Aligos Therapeutics (ALGS) News Today $9.93 +0.09 (+0.91%) Closing price 04:00 PM EasternExtended Trading$10.10 +0.17 (+1.71%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Aligos Therapeutics (NASDAQ:ALGS) Earns "Sell (D-)" Rating from Weiss Ratings3 hours ago | marketbeat.comAligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025October 7 at 10:25 AM | markets.businessinsider.comAligos Therapeutics, Inc. Announces Eight Presentations at The Liver Meeting® 2025, Including Oral Presentation on Novel HBV TherapyOctober 7 at 8:51 AM | quiverquant.comQAligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025October 7 at 8:30 AM | globenewswire.comAligos Therapeutics (NASDAQ:ALGS) Shares Up 5% - Should You Buy?October 2, 2025 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Receives "Buy" Rating from HC WainwrightSeptember 14, 2025 | marketbeat.comTrexquant Investment LP Reduces Stock Holdings in Aligos Therapeutics, Inc. $ALGSSeptember 12, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Boosts Stock Holdings in Aligos Therapeutics, Inc. $ALGSSeptember 9, 2025 | marketbeat.comAlyeska Investment Group L.P. Acquires New Stake in Aligos Therapeutics, Inc. $ALGSSeptember 8, 2025 | marketbeat.comAligos Therapeutics, Inc. $ALGS Shares Sold by EcoR1 Capital LLCSeptember 6, 2025 | marketbeat.comAligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV MeetingSeptember 3, 2025 | globenewswire.comAligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comHeights Capital Management Inc. Takes $1.99 Million Position in Aligos Therapeutics, Inc. $ALGSAugust 30, 2025 | marketbeat.comBrokers Set Expectations for ALGS Q3 EarningsAugust 22, 2025 | marketbeat.comAligos Therapeutics appoints Ramon Polo as head of global regulatory affairsAugust 20, 2025 | msn.comAligos Therapeutics Appoints Ramón Polo as Senior VP, Head of Global Regulatory AffairsAugust 20, 2025 | quiverquant.comQAligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory AffairsAugust 20, 2025 | globenewswire.comAligos Therapeutics assumed with a Buy at H.C. WainwrightAugust 18, 2025 | msn.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 15, 2025 | globenewswire.comAligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME studyAugust 14, 2025 | msn.comAligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV InfectionAugust 13, 2025 | globenewswire.comAligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54)August 7, 2025 | msn.comAligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comAligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash WiselyJuly 31, 2025 | finance.yahoo.comAligos Therapeutics, Inc. to Announce Second Quarter 2025 Financial Results on August 6, 2025July 30, 2025 | quiverquant.comQAligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025July 30, 2025 | globenewswire.comAligos Therapeutics (ALGS) Projected to Post Quarterly Earnings on TuesdayJuly 29, 2025 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Shares Up 1.8% - Time to Buy?July 24, 2025 | marketbeat.comReadystate Asset Management LP Acquires New Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS)July 24, 2025 | marketbeat.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 | globenewswire.comAligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)June 18, 2025 | globenewswire.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 | globenewswire.comAligos Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comAligos Stock Price HistoryMay 26, 2025 | investing.comAligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of LegalMay 20, 2025 | globenewswire.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2025 | globenewswire.comAligos Therapeutics Presents Positive Data at the EASL Congress 2025May 8, 2025 | globenewswire.comAligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.com4ALGS : Aligos Therapeutics's Earnings OutlookMay 6, 2025 | benzinga.comAligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025April 29, 2025 | globenewswire.comAligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025April 23, 2025 | globenewswire.comAligos Therapeutics' (ALGS) "Buy" Rating Reiterated at HC WainwrightApril 1, 2025 | marketbeat.comAligos Therapeutics files to sell 6.25M shares of common stock for holdersMarch 29, 2025 | markets.businessinsider.comA Path to a Healthier Future With Chronic Hepatitis B Virus InfectionMarch 28, 2025 | usatoday.comAligos Therapeutics presents positive data at APASL2025March 27, 2025 | markets.businessinsider.comAligos Therapeutics Presents Positive Data at APASL 2025March 26, 2025 | globenewswire.comTen option delistings on March 24thMarch 24, 2025 | markets.businessinsider.com30,570 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Purchased by Avantax Advisory Services Inc.March 19, 2025 | marketbeat.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 14, 2025 | globenewswire.comAligos Therapeutics Faces Challenges in Developing Hepatitis B Treatments Amidst Industry CompetitionMarch 12, 2025 | tipranks.com Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALGS Media Mentions By Week ALGS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALGS News Sentiment▼0.820.56▲Average Medical News Sentiment ALGS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALGS Articles This Week▼41▲ALGS Articles Average Week Get the Latest News and Ratings for ALGS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aligos Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Heron Therapeutics News Today Kyverna Therapeutics News Today Sagimet Biosciences News Today Tiziana Life Sciences News Today Atea Pharmaceuticals News Today Entrada Therapeutics News Today Cabaletta Bio News Today Black Diamond Therapeutics News Today Enanta Pharmaceuticals News Today Caribou Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALGS) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredAn Early Move On The Next Shift In CoinLitecoin is already processing 500,000+ daily transactions, integrated with PayPal and Revolut, and now one fi...Market Tactic | Sponsored"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
